Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

NCT05399459 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

897

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: Rimegepant 25 MG
DRUG: Rimegepant 75 MG
DRUG: Placebo

Sponsor

Pfizer